Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in ...

Dr. Sattva S. Neelapu discusses the intricacies of CAR T-cell therapy treatment and care for patients with hematologic ...

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...

The company states: “Kite, a Gilead (GILD) Company, announced results from a five-year follow-up analysis of ZUMA-5, a Phase 2 study of Yescarta in patients with relapsed/refractory non-Hodgkin ...

Curocell launches Limcato, South Koreas first domestic CAR-T cancer therapy Curocell introduces first local CAR-T therapy, ...

The Scottish Medicines Consortium has backed NHS funding for Gilead’s CAR-T therapy Yescarta for B-cell lymphomas, a few months after it was given the okay south of the border. Yescarta ...

Scotland’s cost-effectiveness watchdog has decided against making Gilead’s CAR-T therapy Yescarta routinely available to patients with two types of lymphoma, but gave a green light to Novartis ...

Gilead stock rated buy for thriving HIV biz, promising oncology pipeline, and long-term growth potential despite volatility.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...